GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sansure Biotech Inc (SHSE:688289) » Definitions » Return-on-Tangible-Asset

Sansure Biotech (SHSE:688289) Return-on-Tangible-Asset : 1.89% (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Sansure Biotech Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Sansure Biotech's annualized Net Income for the quarter that ended in Sep. 2024 was ¥155 Mil. Sansure Biotech's average total tangible assets for the quarter that ended in Sep. 2024 was ¥8,207 Mil. Therefore, Sansure Biotech's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2024 was 1.89%.

The historical rank and industry rank for Sansure Biotech's Return-on-Tangible-Asset or its related term are showing as below:

SHSE:688289' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -1.92   Med: 6.74   Max: 86.36
Current: 3.16

During the past 7 years, Sansure Biotech's highest Return-on-Tangible-Asset was 86.36%. The lowest was -1.92%. And the median was 6.74%.

SHSE:688289's Return-on-Tangible-Asset is ranked better than
61.98% of 868 companies
in the Medical Devices & Instruments industry
Industry Median: -2.49 vs SHSE:688289: 3.16

Sansure Biotech Return-on-Tangible-Asset Historical Data

The historical data trend for Sansure Biotech's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sansure Biotech Return-on-Tangible-Asset Chart

Sansure Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial 6.74 86.36 35.96 24.01 4.23

Sansure Biotech Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.22 3.14 3.92 3.63 1.89

Competitive Comparison of Sansure Biotech's Return-on-Tangible-Asset

For the Medical Instruments & Supplies subindustry, Sansure Biotech's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sansure Biotech's Return-on-Tangible-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sansure Biotech's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Sansure Biotech's Return-on-Tangible-Asset falls into.



Sansure Biotech Return-on-Tangible-Asset Calculation

Sansure Biotech's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=363.721/( (9089.321+8118.577)/ 2 )
=363.721/8603.949
=4.23 %

Sansure Biotech's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=154.884/( (8279.476+8134.999)/ 2 )
=154.884/8207.2375
=1.89 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2024) net income data.


Sansure Biotech  (SHSE:688289) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Sansure Biotech Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Sansure Biotech's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Sansure Biotech Business Description

Traded in Other Exchanges
N/A
Address
No. 680, Lusong Road, Changsha High-tech Industrial Development Zone, Hunan Province, Changsha, CHN, 410205
Sansure Biotech Inc is engaged in production and sales of diagnostic reagents and instruments. The company produces Class I medical devices, Class II medical devices, Class III medical devices, general instruments and meters, medical raw materials, medical laboratory equipment and appliances, and medical accessories.
Executives
Tan De Yong Core technical personnel
Wang Hai Xiao senior management
Jie Ya Ping Core technical personnel
Zhang Ke Ya Core technical personnel
Yang Li Core technical personnel
Liu Rang Jiao Core technical personnel
Deng Zhong Ping Senior management, core technical personnel
Zhou Jun senior management
Zhu Jian senior management
Wu Kang Core technical personnel
Xiong Xiao Yan senior management
Ji Bo Zhi Core technical personnel
Mou Wei Min Core technical personnel
Ren Xiao Mei Core technical personnel
Liu Kai senior management

Sansure Biotech Headlines

No Headlines